All News

STEP 1 and STEP 3 Results with Thomas Wadden, PhD

March 02, 2021

Published in late February, results of the STEP 1 and STEP 3 trial give clinicians insight into the effects of 2.4 mg subcutaneous semaglutide as an intervention for weight loss in overweight or obese patients ahead of a potential approval in June 2021.

Digital Self-Monitoring Linked to Improvements in Weight Loss Trials

February 24, 2021

A review of 39 randomized clinical trials examining weight loss interventions is providing clinicians with an overview of engagement rates, mediums used, and effects of digital self-monitoring for weight loss among obese or overweight patients.

When Men Exercise Could Influence Risk of Cardiovascular Disease, Study Finds

February 23, 2021

An analysis of more than 2k patients from within the Look AHEAD study suggests the timing of physical activity could play a role in mitigating cardiovascular risk among men with type 2 diabetes considered overweight or obese.

Case Report: Shortness of Breath After Cefalexin

February 18, 2021

Our latest case report from Brady Pregerson, MD, features a 62 y/o male with a history of obesity, CAD, anxiety, and COPD presenting with SOB after stating cefalexin. Can you determine the correct diagnosis?